The authors demonstrated increased expression of collagen IV, perlecan and fibronectin in patients with subclinical AD and AD, compared to the control group, in the frontal and temporal cortex, while no further increase was detected between subclinical AD and AD. The gene discussed is HSPG2; the disease is Alzheimer disease.